Dear Honorable Members of the Korean Society of Nuclear Medicine!

Founded in 1961, the Korean Society of Nuclear Medicine (KSNM) continues to evolve and lead the world with its members' leadership and challenging efforts. In particular, PET/CT has significantly contributed to the expansion and development of nuclear medicine over the past 20 years. However, unfortunately, we are now facing adversity due to the reduction of insurance coverage, job losses, and lack of new applicants. However, nuclear medicine treatment worldwide dreams of a new revival with theranostics at the forefront. In Korea, Lutatera, a radionuclide therapy for neuroendocrine tumors, has been introduced in clinics, and PMSA-targeted treatment for prostate cancer is undergoing clinical trials.
More encouraging is that not only drugs developed in foreign countries but also domestically developed nuclear medicine diagnoses and treatments are undergoing clinical trials. In response, KSNM should play a pivotal role in creating a place by promoting convergence research between nuclear medicine scientists and physicians, attracting investment from the government and companies, and new practice approval and insurance coverage. In addition, we will strive to spread new research and practice through education and training, become trusted by clinicians and patients through quality assurance, and secure clinical evidence backgrounds. KSNM will improve people's quality of life by promoting communication among members, other professional fields, governments, companies, patients, and the public. Today's adversity will lead to the fruits of the future if we work together.